Clinical Trials Logo
  1. Home
  2. Lung Cancer Metastatic
  3. NCT06060262

The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer

Lung Cancer Metastatic Clinical Trial

Official title:
The Clinical Significance of Metabolic Adipo-myokines and Alterations of Body Composition in Patients With End Stage Lung Cancer

Clinical Trial Summary

The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis

Clinical Trial Description

Recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. What's more important is that muscles could synthesize and release adipo-myokines during contraction. The adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.Studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance. Since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. Therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06060262
Study type Observational
Source Chang Gung Memorial Hospital
Contact TSENG CHIA-CHENG
Phone +886 7 731 7123
Email cctseng@hotmail.com.tw
Status Recruiting
Phase
Start date February 2, 2023
Completion date November 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05452005 - Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer Phase 1
Completed NCT03179150 - Clinical Validation of the M5L Lung CAD N/A
Recruiting NCT03693339 - Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation Phase 2
Completed NCT03970564 - Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Terminated NCT02308865 - Early Palliative Care in Metastatic Lung Cancer in Northern France N/A
Not yet recruiting NCT03703596 - Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC Phase 2
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Completed NCT04233476 - A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient Phase 3
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT03755102 - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Early Phase 1
Not yet recruiting NCT03638765 - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer Phase 1
Recruiting NCT02976740 - SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy Phase 2
Active, not recruiting NCT04085315 - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Phase 1
Recruiting NCT03693326 - PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities Phase 2
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Active, not recruiting NCT04964960 - Pembro+Chemo in Brain Mets Phase 2
Active, not recruiting NCT04973436 - DBT for Metastatic Lung Cancer N/A
Recruiting NCT05078047 - Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO Phase 3